Poland· PL-100427468
Spravato
A esketamine product containing esketaminum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Esketamine is registered in 11 of 19 countries.
Countries holding a registration under ATC N06AX27 (esketamine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Esketamine · ATC N06AX27
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of esketamine costs, country by country.
Normalised to the WHO defined daily dose (8 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Esketamine · price per daily dose (8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$66.47
The record
At a glance
URPL (Poland)- Active substance
- Esketaminum
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- N06AX27
- ATC class
- Esketamine
- Defined daily dose
- 8 mg, N
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05413868117400
- gtin05413868117417
- gtin05413868117424
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
91 interactions on record for esketamine.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Esketamine · interactions on record
91 records
- 7 severe
- 84 moderate
Most severe, free to view
- PhentermineA08AA01severe
- FenfluramineA08AA02severe
- MazindolA08AA05severe
- FenfluramineN03AX26severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Esketamine in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandSpravato, Nasenspray, LösungJanssen-Cilag AG
- SpainSPRAVATO 28 MG SOLUCION PARA PULVERIZACION NASALJanssen-Cilag International N.V
- FinlandSpravatoJanssen-Cilag International NV
- FranceSPRAVATO 28 mg, solution pour pulvérisation nasaleJANSSEN CILAG INTERNATIONAL NV
- NetherlandsSpravato 28 mg neusspray, oplossingJanssen-Cilag International NV
- NorwaySpravatoJanssen-Cilag International N.V.
- BelgiumSpravato 28 mgJanssen-Cilag International
- SwedenSpravato 28 mg Nässpray, lösningJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Austria · Escetex, Eskelan
- Belgium · Esketamine Kalceks, Vesierra
- Germany · Esketamin, Esketamin Inresa
- Denmark · Esketamine Orifarm, S-Ketamin Pfizer
- Estonia · Esketex
- Finland · Esketamine Kalceks, Esketamine Orifarm
- France · Eskesia, Esketamine Renaudin
- United Kingdom (Northern Ireland) · Esketamine Idd, Esketamine Kalceks
- Croatia · Esgamda
- Iceland · S-Ketamin Pfizer, Spravato
- Liechtenstein · Spravato
- Luxembourg · Vesierra
- Latvia · Esketamine Kalceks
- Netherlands · Esketamine Focus, Esketamine Idd
- Norway · Ketanest, Sinmelan
- Sweden · Esketamine Kalceks, Esketamine Orifarm
- Slovenia · Esketamin Kalceks, Sinmelan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf6d5873-78c5-4626-80c9-d33ef4ec46bd GET /v1/drugs/bf6d5873-78c5-4626-80c9-d33ef4ec46bd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Aerozol do nosa, roztwór",
"source": "urpl",
"strength": "28 mg",
"packaging": "05413868117400 ¦ Rpw ¦ EU/1/19/1410/001 ¦ 134592\n1 fiol. 28 mg\n05413868117417 ¦ Rpw ¦ EU/1/19/1410/002 ¦ 134593\n2 fiol. 28 mg\n05413868117424 ¦ Rpw ¦ EU/1/19/1410/003 ¦ 134594\n3 fiol. 28 mg\nRpw ¦ EU/1/19/1410/004 ¦ 135116\n6 fiol. 28 mg\nRpw ¦ EU/1/19/1410/005 ¦ 148261\n24 fiol. 28 mg (opak. zbiorcze)\nRpw ¦ EU/1/19/1410/006 ¦ 148262\n12 fiol. 28 mg (opak. zbiorcze)",
"substance": "Esketaminum 28 mg",
"common_name": "Esketaminum",
"pl_product_id": "100427468",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about esketamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.